Find Clinical Trial

Evaluation of the effects on heart rate, haemodynamic parameters, safety and tolerability of 5 mg bolus of ivabradine followed by 8-hour infusion at the dose of 5 mg of ivabradine given after a percutaneous coronary intervention following a myocardial infarction with ST segment elevation


← Back
Study Phase

Phase 2

Therapeutic Area

Cardiovascular Diseases

Active substance/
Medical device

S016257, IVABRADINE

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS016257
Protocol CodeCL2-16257-060
EudraCT Code2005-005122-31
ISRCTN CodeISRCTN66067800


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility